Overview of New Therapeutic Developments for Acne

Anja Thielitz; Harald Gollnick


April 13, 2009

In This Article

Dapsone Gel

A new aqueous gel formulation of dapsone 5% (Aczone®, QLT Inc., BC, Canada) was approved by the FDA in 2005. The efficacy and safety of twice-daily dapsone 5% gel versus a vehicle gel in the treatment of acne was evaluated in 3010 patients 12 years of age and older with acne vulgaris in two identically designed 12-week, randomized, double-blind studies. In these studies, dapsone gel-treated patients achieved superior results in terms of the investigator's global acne assessment (p < 0.001) and the mean percentage reduction in inflammatory, noninflammatory and total lesion counts (p < 0.001) at week 12.[46] No clinically significant changes in laboratory parameters, including hemoglobin, even among glucose-6-phosphate dehydrogenase-deficient patients, were observed. The most common adverse events include oiliness/peeling, dryness and erythema. There were no significant differences in the adverse event rates between dapsone gel- and vehicle control-treated patients. Another 12-month, open-label, long-term safety study further evaluated the safety and efficacy of dapsone gel in patients at least 12 years of age with acne vulgaris (n = 486).[47] Application-site reactions related to treatment were reported in 8.2% of the patients and were mostly mild to moderate in severity. The mean reduction from baseline at 12 months was 58.2% for inflammatory, 19.5% for noninflammatory and 49.0% for total lesion counts (all p = 0.002).


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: